DINESH

Medplus Health Services

Industry: Retail
Latest CMP 669
Today's Change ▲ 0.16%
52-Week High / Low 954 | 668
Price Date: 14-Aug-2026
Recommendation Buy
Target Price 949
Expected Upside 19.1%
Forecast Horizon 2 Years
Historical CAGR Not Available
1,000 Invested
Today's Value
Investment Period < 5 Years

Stock Snapshot

Post Results Return
-14.3%
Negative Re-rating
1-Year Target Price
818
2-Year Target Price
949
52-Week High / Low
954 / 668
20-Day Return
-16.5%
Market Cap (Cr.)
8,037
Current PE
43.5
P/BV Ratio
4.1
Dividend Yield
Industry PE
61.5

Price Performance

Basis of our Recommendation

MedPlus Health Services is strategically transitioning towards a capital-efficient growth model, focusing on expanding its franchisee network and enhancing its private label offerings. Management's commitment to increasing the number of stores to 800 by FY27, alongside optimizing supply chain efficiencies, is expected to drive revenue growth and maintain stable margins. The company's emphasis on a robust omni-channel platform and targeted expansion in Tier-Two markets positions it well to capture a larger market share. Vista's financial outlook reflects a stable revenue growth trajectory, with margins expected to remain consistent, supported by the company's debt-free status and operational efficiencies. The retail sector's recovery and improving pricing power further bolster MedPlus's competitive position. However, execution risks related to store management and inventory remain watchpoints. Over the next 12-24 months, key opportunities include the successful rollout of the private label strategy and expansion into new markets, while headwinds may arise from potential supply chain disruptions and competitive pressures in the retail pharmacy landscape

👍 Why We Like This Stock

  • Management's aggressive expansion plan to add 800 stores by FY27 supports revenue growth
  • Focus on enhancing private label offerings is expected to improve gross margins
  • The company's debt-free status provides significant flexibility for future investments

Things To Watch Out For

  • Execution risks related to store closures and inventory management could impact performance
  • Intense competition in the retail pharmacy sector may pressure market share
  • Potential supply chain disruptions could affect product availability and margins

Key Parameters

Balance Sheet Strength
Stable Financial Structure
Market Share
Stable
Industry Outlook
Improving
Analyst View
Not Available
Dividend History
No Dividend History
FII Holdings
Reducing

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 5,625 6,136 6,892 7,400 8,401
Profit Before Tax (Cr.) 69 177 275 298 338
PBT Margin 1.2% 2.9% 399.0% 4.0% 4.0%
Net Profit (Cr.) 44 131 198 215 243
Earnings Per Share 3.6 10.9 16.5 17.9 20.2

Analyst Recommendations

Broker Recommendation Target Price Date
HDFC Securities ▲ Buy 1,100 22-May-2026
Consensus Recommendation ► None
Consensus Target
Coverage 1 Analysts
Analysts' Viewpoint

Company Overview

Show Company Profile

MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.